HALOZYME THERAPEUTICS, INC.

Licenses a drug delivery platform to biopharma, converting IV drugs to subcutaneous injections.

HALO | NDAQ

Overview

Corporate Details

ISIN(s):: US40637H1095
LEI:
Country:: United States of America
Address:: 12390 EL CAMINO REAL, 92130 SAN DIEGO
Website:: https://www.halozyme.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Halozyme Therapeutics, Inc. is a biotechnology company focused on its proprietary drug delivery technology platform, ENHANZE®. This technology facilitates the subcutaneous (under-the-skin) delivery of injectable drugs and biologics that are often administered intravenously. Halozyme licenses its ENHANZE® technology to global biopharmaceutical companies, enabling them to develop new formulations of their therapies. This model aims to reinvent the patient experience by reducing treatment burden and shortening administration times, particularly in therapeutic areas such as oncology. The company's commercial portfolio is primarily built on royalties and milestone payments derived from its partners' sales of products utilizing the ENHANZE® platform.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all HALOZYME THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HALOZYME THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for HALOZYME THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Heidelberg Pharma AG Develops cancer therapies using its proprietary ATAC Antibody-Drug Conjugate technology.	Germany	HPHA
HighCo Data marketing firm offering digital solutions for brands & retailers to influence shopper behavior.	France	HCO
HireQuest, Inc. A franchisor of staffing solutions offering temporary labor and skilled placement to diverse industries.	United States of America	HQI
H.I.S. Co., Ltd. A major Japanese travel agency providing global tour packages, lodging, and transport.	Japan	9603
Hit Co., Ltd. Specialized OOH advertising firm providing digital & static billboards in high-visibility areas.	Japan	378A
HLB Therapeutics Co.,Ltd. Develops innovative drugs for rare eye diseases and brain tumors, with vaccine logistics.	South Korea	115450
HONYAKU Center Inc. Provides industrial translation and interpreting for patent, legal, and corporate clients.	Japan	2483
HS HYOSUNG Corporation A holding company for advanced materials, AI/data solutions, mobility, and global logistics.	South Korea	487570
Human Metabolome Technologies, Inc. A leader in metabolomics, providing CE-MS analysis to support R&D in biotech, pharma, and food.	Japan	6090
Hybrigenics SA R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.	France	ALHYG